Thermo Fisher Scientific Inc. $TMO Stake Boosted by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,334 shares of the medical research company's stock after purchasing an additional 1,816 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in Thermo Fisher Scientific were worth $13,921,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Concord Wealth Partners boosted its holdings in shares of Thermo Fisher Scientific by 39.5% during the second quarter. Concord Wealth Partners now owns 113 shares of the medical research company's stock valued at $46,000 after acquiring an additional 32 shares during the period. Vest Financial LLC grew its position in Thermo Fisher Scientific by 39.3% in the 2nd quarter. Vest Financial LLC now owns 4,440 shares of the medical research company's stock worth $1,800,000 after purchasing an additional 1,252 shares during the last quarter. MGO One Seven LLC increased its stake in shares of Thermo Fisher Scientific by 26.7% in the second quarter. MGO One Seven LLC now owns 3,204 shares of the medical research company's stock valued at $1,299,000 after purchasing an additional 676 shares during the period. Cypress Capital Group bought a new stake in shares of Thermo Fisher Scientific during the second quarter valued at approximately $479,000. Finally, Bill Few Associates Inc. grew its holdings in Thermo Fisher Scientific by 6.3% in the 2nd quarter. Bill Few Associates Inc. now owns 588 shares of the medical research company's stock worth $238,000 after buying an additional 35 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $524.80 on Tuesday. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The firm's 50 day moving average price is $489.83 and its two-hundred day moving average price is $447.66. The firm has a market cap of $198.17 billion, a price-to-earnings ratio of 30.35, a price-to-earnings-growth ratio of 2.85 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same period in the previous year, the firm posted $5.37 EPS. The company's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the sale, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 over the last ninety days. 0.33% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a research note on Friday, July 11th. Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a report on Thursday, July 24th. Barclays raised their target price on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an "overweight" rating in a research note on Thursday, October 2nd. Wall Street Zen cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday. Finally, Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Fifteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $589.10.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.